Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAIME G DEVILLE

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1750301503
CMS profile
306772
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$119.70

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $119.70 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
ViiV Healthcare Company $119.70 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAIME G DEVILLE

NPI 1750301503 · CMS profile ID 306772

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750301503?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAIME G DEVILLE, NPI 1750301503, CMS profile ID 306772. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750301503?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JAIME G DEVILLE, NPI 1750301503, CMS profile ID 306772. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750301503?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JAIME G DEVILLE, NPI 1750301503, CMS profile ID 306772, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1750301503?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $119.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ViiV Healthcare Company $119.7010/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671586299 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $119.70 1
PY2023 $12,707.12 13
PY2024 $184.08 4
PY2025 $2,569.53 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,582.34 15
PY2025 Principal investigator $260,502.25 43
PY2024 Principal investigator $147,535.10 28
PY2023 Recipient $2,359.23 6
PY2023 Principal investigator $286,959.88 51
PY2022 Principal investigator $147,785.97 35
PY2021 Recipient $31,165.00 1
PY2021 Principal investigator $320,361.44 168
PY2020 Principal investigator $484,980.10 158
PY2019 Principal investigator $153,612.59 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ViiV Healthcare Company $252.00 12/23/2023 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 1003094892
Principal investigator 1 Gilead Sciences, Inc. $1,852.00 12/20/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 1025370527
Principal investigator 1 Gilead Sciences, Inc. $358.00 12/11/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 1025370521
Principal investigator 1 PFIZER INC. $118.00 11/30/2023 Non-covered Recipient Entity
UCLA DAVID GEFFEN SCHOOL OF
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1046138569
Principal investigator 1 Gilead Sciences, Inc. $69.00 11/28/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 1025370515
Principal investigator 1 PFIZER INC. $18,662.00 11/09/2023 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1045948755
Principal investigator 1 ViiV Healthcare Company $2,562.15 10/24/2023 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 1003094913
Recipient Astellas Pharma Global Development $575.36 10/20/2023 Covered Recipient Physician A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants No dispute reported 06/30/2026 1022245891
Recipient Astellas Pharma Global Development $338.44 10/20/2023 Covered Recipient Physician A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants No dispute reported 06/30/2026 1022245901
Recipient Astellas Pharma Global Development $203.47 10/20/2023 Covered Recipient Physician A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants No dispute reported 06/30/2026 1022245911
Principal investigator 1 Gilead Sciences, Inc. $1,776.00 10/18/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 1025370509
Principal investigator 1 ViiV Healthcare Company $12,600.00 10/17/2023 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 1003094849
Principal investigator 1 ViiV Healthcare Company $630.00 10/12/2023 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 1003094807
Principal investigator 1 ViiV Healthcare Company $609.51 10/12/2023 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 1003094935
Principal investigator 1 ViiV Healthcare Company $3,170.49 10/12/2023 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 1003095311
Principal investigator 1 PFIZER INC. $756.41 09/23/2023 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045887187
Principal investigator 1 Gilead Sciences, Inc. $1,830.00 09/20/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 1025370503
Principal investigator 1 Gilead Sciences, Inc. $1,789.00 08/25/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 1025370497
Principal investigator 1 Astellas Pharma Global Development $630.00 08/23/2023 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 1022250049
Recipient Astellas Pharma Global Development $851.23 08/18/2023 Covered Recipient Physician A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants No dispute reported 06/30/2026 1022245879
Principal investigator 1 PFIZER INC. $240.00 08/17/2023 Non-covered Recipient Entity
Ronald Reagan UCLA Med Ctr
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1046108219
Principal investigator 1 ViiV Healthcare Company $2,528.83 08/17/2023 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 1003094871
Principal investigator 1 ViiV Healthcare Company $2,867.70 08/15/2023 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 1003094829
Principal investigator 1 ViiV Healthcare Company $630.00 08/15/2023 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 1003095241
Principal investigator 1 ViiV Healthcare Company $31.83 08/15/2023 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 1003095263
Principal investigator 1 ViiV Healthcare Company $880.47 08/15/2023 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA
OPEN-LABEL ACCESS TO DOLUTEGRAVIR FOR HIV-1 INFECTED CHILDREN AND ADOL No dispute reported 06/30/2026 1003095285
Principal investigator 1 Merck Sharp & Dohme LLC $910.80 08/07/2023 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
STUDY NAME#IMPAACT P1115, Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission# A Phase I,II Proof of Concept Study No dispute reported 06/30/2026 1042488259
Principal investigator 1 GlaxoSmithKline, LLC. $3,508.64 08/04/2023 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127785641
Principal investigator 1 Astellas Pharma Global Development $11,860.00 08/03/2023 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 1022250061
Principal investigator 1 PFIZER INC. $1,575.00 07/26/2023 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045887201
Principal investigator 1 Gilead Sciences, Inc. $4,827.00 07/19/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 1025370491
Principal investigator 1 Hoffmann-La Roche Limited $3,150.00 07/18/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040189931
Principal investigator 1 Gilead Sciences, Inc. $5,639.00 07/10/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 No dispute reported 06/30/2026 1025370485
Principal investigator 1 PFIZER INC. $2,500.00 06/30/2023 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 1046207885
Principal investigator 1 Hoffmann-La Roche Limited $6,508.00 06/27/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040189917
Principal investigator 1 Gilead Sciences, Inc. $1,852.00 06/21/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 1025370479
Principal investigator 1 GlaxoSmithKline, LLC. $25,614.28 06/16/2023 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1006238247
Principal investigator 1 GlaxoSmithKline, LLC. $2,998.34 06/16/2023 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1006238253
Recipient Astellas Pharma Global Development $169.65 05/18/2023 Covered Recipient Physician A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants No dispute reported 06/30/2026 1022245933
Principal investigator 1 Hoffmann-La Roche Limited $4,662.00 05/02/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040189875
Principal investigator 1 Hoffmann-La Roche Limited $2,500.00 05/02/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040189892
Principal investigator 1 Hoffmann-La Roche Limited $441.00 05/02/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040189907
Principal investigator 1 PFIZER INC. $3,150.00 04/27/2023 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045887219
Recipient Astellas Pharma Global Development $221.08 04/19/2023 Covered Recipient Physician A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants No dispute reported 06/30/2026 1022245923
Principal investigator 1 Gilead Sciences, Inc. $4,502.00 04/17/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 No dispute reported 06/30/2026 1025370473
Principal investigator 1 AstraZeneca Pharmaceuticals LP $46,553.00 04/06/2023 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Open-label, Uncontrolled, Single dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ? 29 Weeks Gestational Age to < 18 Years No dispute reported 06/30/2026 991124299
Principal investigator 1 PFIZER INC. $2,225.78 03/30/2023 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045889259
Principal investigator 1 Hoffmann-La Roche Limited $17,955.00 03/14/2023 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040192513
Principal investigator 1 Hoffmann-La Roche Limited $4,158.00 03/14/2023 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase I PK PD safety and efficacy study of open label tocilizumab in children with COVID 19 No dispute reported 06/30/2026 1040192527
Principal investigator 1 PFIZER INC. $1,594.00 02/28/2023 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1046285951
Principal investigator 1 Gilead Sciences, Inc. $9,450.00 02/13/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 1025370467
Principal investigator 1 PFIZER INC. $18,774.41 02/09/2023 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045889273
Principal investigator 1 ModernaTX, Inc. $1,701.24 01/20/2023 Non-covered Recipient Entity
LOS ANGELES CHILDRENS HOSPITAL
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1041231599
Principal investigator 1 PFIZER INC. $1,323.00 01/19/2023 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1046350559
Principal investigator 1 PFIZER INC. $28,741.00 01/12/2023 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1046349729
Principal investigator 1 Astellas Pharma Global Development $6,575.00 01/11/2023 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects No dispute reported 06/30/2026 1022250071
Principal investigator 1 Gilead Sciences, Inc. $6,868.00 01/04/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 No dispute reported 06/30/2026 1025370459